Trinity team attends Battle Summit to hear how Cycle for Survival funding is helping rare cancer patients

Trinity’s Breanna Liponis and Alyssa Blaize recently attended Battle Summit to hear firsthand from Memorial Sloan Kettering doctors and researchers how Cycle for Survival funding is helping rare cancer patients everywhere. The team heard about important studies, initiatives and clinical trials funded through Cycle for Survival donors and participants for salivary gland cancer, pancreatic neuroendocrine tumors and advanced melanoma, among other areas. In addition, the team heard the latest updates on Loxo Oncology’s TRK fusion inhibitor, larotrectinib, developed with Cycle for Survival funding, and its path to FDA approval. At Trinity, we are proud to support Cycle for Survival to help advance rare cancer research. Learn more about Cycle for Survival: https://bit.ly/2KqaFmI and read more about larotrectinib in our latest whitepaper: https://bit.ly/2lCatD5

See all News posts